Pub. Date : 2014
PMID : 25009787
5 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | We tested if dimethylfumarate (DMF), an anti-psoriasis drug, could inhibit abnormal vascular remodeling via NF-E2-related factor 2 (Nrf2)-NAD(P)H quinone oxidoreductase 1 (NQO1) activity. | Dimethyl Fumarate | NAD(P)H quinone dehydrogenase 1 | Homo sapiens |
| 2 | We tested if dimethylfumarate (DMF), an anti-psoriasis drug, could inhibit abnormal vascular remodeling via NF-E2-related factor 2 (Nrf2)-NAD(P)H quinone oxidoreductase 1 (NQO1) activity. | Dimethyl Fumarate | NAD(P)H quinone dehydrogenase 1 | Homo sapiens |
| 3 | We tested if dimethylfumarate (DMF), an anti-psoriasis drug, could inhibit abnormal vascular remodeling via NF-E2-related factor 2 (Nrf2)-NAD(P)H quinone oxidoreductase 1 (NQO1) activity. | Dimethyl Fumarate | NAD(P)H quinone dehydrogenase 1 | Homo sapiens |
| 4 | We tested if dimethylfumarate (DMF), an anti-psoriasis drug, could inhibit abnormal vascular remodeling via NF-E2-related factor 2 (Nrf2)-NAD(P)H quinone oxidoreductase 1 (NQO1) activity. | Dimethyl Fumarate | NAD(P)H quinone dehydrogenase 1 | Homo sapiens |
| 5 | In conclusion, DMF prevented abnormal proliferation in VSMCs by G1 cell cycle arrest via p21 upregulation driven by Nrf2 and p53 activity, and had a beneficial effect on TNF-alpha-induced apoptosis and dysfunction in endothelial cells through Nrf2-NQO1 activity suggesting that DMF might be a therapeutic drug for patients with vascular disease. | Dimethyl Fumarate | NAD(P)H quinone dehydrogenase 1 | Homo sapiens |